Natalie Mount
InvestorVenture Partner at Abingworth · Board director at Wugen
Find your path to Natalie
53 people in our graph share verified history with Natalie — schools, employers, funds. One of them is your warm intro.
About
Natalie Mount joined Abingworth as a Venture Partner in August 2022. She previously served as CEO of Adaptate Biotherapeutics and CSO of GammaDelta Therapeutics, both Abingworth-founded companies, and was a founding team member and Chief Clinical Officer at the Cell and Gene Therapy Catapult. Earlier she spent 16 years at Pfizer leading development activities including cell-based therapies in its Regenerative Medicine Unit. She holds a degree in Natural Sciences from the University of Cambridge and a Ph.D. from University College London.
Invests in
Biotech
Board director at Wugen
Intro paths
In turn, Natalie can intro founders to Wugen's investors below.
Wugen's investors · 8
Deals · 1
Allotera Therapeutics, Inc.Board seat
via Abingworth · filed Jul 2026 · $163M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at Abingworth
Frequently asked questions
- Who is Natalie Mount?
- Natalie Mount joined Abingworth as a Venture Partner in August 2022. She previously served as CEO of Adaptate Biotherapeutics and CSO of GammaDelta Therapeutics, both Abingworth-founded companies, and was a founding team member and Chief Clinical Officer at the Cell and Gene Therapy Catapult. Earlier she spent 16 years at Pfizer leading development activities including cell-based therapies in its Regenerative Medicine Unit. She holds a degree in Natural Sciences from the University of Cambridge and a Ph.D. from University College London.
- Where does Natalie Mount work?
- Natalie Mount is Venture Partner at Abingworth and Board director at Wugen.
- What does Natalie Mount invest in?
- Natalie Mount invests in Biotech.
- What boards does Natalie Mount sit on?
- Natalie Mount holds tracked board seats at Allotera Therapeutics, Inc..